Evidence map›Paper›PMID 38861384›Full record

ArticleCell reports2024

Endogenous p53 inhibitor TIRR dissociates systemic metabolic health from oncogenic activity.

Eva Tsaousidou, Jędrzej Chrzanowski, Pascal Drané, Grace Y Lee, Nadine Bahour, Zeqiu Branden Wang, Shijun Deng, Zhe Cao, Kaimeng Huang, Yizhou He and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Eva TsaousidouSabri Ülker Center for Metabolic Research, Department of Molecular Metabolism, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA; Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Jędrzej ChrzanowskiDepartment of Biostatistics and Translational Medicine, Medical University of Lodz, 92-215 Lodz, Poland.
Pascal DranéDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Grace Y LeeSabri Ülker Center for Metabolic Research, Department of Molecular Metabolism, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
Nadine BahourSabri Ülker Center for Metabolic Research, Department of Molecular Metabolism, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
Zeqiu Branden WangSabri Ülker Center for Metabolic Research, Department of Molecular Metabolism, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
Shijun DengSabri Ülker Center for Metabolic Research, Department of Molecular Metabolism, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
Zhe CaoSabri Ülker Center for Metabolic Research, Department of Molecular Metabolism, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
Kaimeng HuangDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Yizhou HeDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Mateusz KaminskiDepartment of General Surgery, Medical University of Lodz, 90-153 Lodz, Poland.
Dominika MichalekDepartment of Biostatistics and Translational Medicine, Medical University of Lodz, 92-215 Lodz, Poland.
Ekin GüneySabri Ülker Center for Metabolic Research, Department of Molecular Metabolism, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
Kalindi ParmarDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Wojciech FendlerDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Department of Biostatistics and Translational Medicine, Medical University of Lodz, 92-215 Lodz, Poland.
Dipanjan ChowdhuryDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA. Electronic address: dipanjan_chowdhury@dfci.harvard.edu.
Gökhan S HotamışlıgilSabri Ülker Center for Metabolic Research, Department of Molecular Metabolism, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA. Electronic address: ghotamis@hsph.harvard.edu.

Funding

Training Program in Translational Brain Tumor ResearchT32CA151022 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2010 to 2026
$6.6M
Elucidating the molecular mechanism and physiological relevance of TIRR mediated inhibition of p53R01CA264900 · NCI · DANA-FARBER CANCER INST · PI Dipanjan Chowdhury · 2022 to 2026
$1.9M
Investigating 53BP1 'dephosphorylation' as a critical determinant of PARPR01CA208244 · NCI · DANA-FARBER CANCER INST · PI CHOWDHURY, DIPANJAN · 2017 to 2021
$1.9M
NCI NIH HHS R01 CA208244NCI NIH HHS R01 CA264900NCI NIH HHS T32 CA151022
6 · The paper itself

Abstract

It is unclear whether metabolic health corresponds to reduced oncogenesis or vice versa. We study Tudor-interacting repair regulator (TIRR), an inhibitor of p53 binding protein 1 (53BP1)-mediated p53 activation, and the physiological consequences of enhancing tumor suppressor activity. Deleting TIRR selectively activates p53, significantly protecting against cancer but leading to a systemic metabolic imbalance in mice. TIRR-deficient mice are overweight and insulin resistant, even under normal chow diet. Similarly, reduced TIRR expression in human adipose tissue correlates with higher BMI and insulin resistance. Despite the metabolic challenges, TIRR loss improves p53 heterozygous (p53

Indexed as

CarcinogenesisRNA-Binding ProteinsTumor Suppressor Protein p53Adipose TissueAnimalsGlucoseHumansInsulin ResistanceMaleMiceMice, Inbred C57BLMice, KnockoutGlucoseNUDT16L1 protein, humanRNA-Binding ProteinsTumor Suppressor Protein p53cancer metabolismcancer mouse model of p53 activationcancer protectionCP: CancerCP: Metabolismin vivo physiology in cancermevalonate pathway suppressionobesity and canceroverweight and cancerp53 activationp53 derepressionp53 inhibitortype 2 diabetes and cancer

Identifiers

PMID38861384
PMCPMC11325268

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.